ERYTECH Announces Filing of
2021 Universal Registration Document and
2021 Annual Report on Form 20-F,
as well as its 2022 financial calendar
These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the Universal Registration Document is available on the website of the AMF (www.amf-france.org) and the Annual Report on Form 20-F is also available on the website of the
Financial Calendar 2022*
- Business Update and Financial Highlights for the First Quarter of 2022:
May 12, 2022 (after U.S. market close), followed by a conference call & webcast onMay 13, 2022 (2:30pm CET /8:30am ET ) - Shareholders’ Meeting:
June 24, 2022 at9.00am CET -Paris - Business Update and Financial Highlights for the
Second Quarter & First Half of 2022:September 12, 2022 (after U.S. market close), followed by a conference call & webcast onSeptember 13, 2022 (2:30pm CET /8:30am ET ) - Business Update and Financial Highlights for the Third Quarter of 2022:
November 8, 2022 (after U.S. market close), followed by a conference call & webcast onNovember 9, 2022 (2:30pm CET /8:30am ET )
(*) : Information subject to change.
About ERYTECH and GRASPA®
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase (GRASPA®), which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in
Eryaspase received Fast Track designation from the
ERYTECH produces its product candidates for treatment of patients in
ERYTECH is listed on the Nasdaq Global Select Market in
For more information, please visit www.erytech.com
CONTACTS
ERYTECH CFO & COO | NewCap Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com | +33 1 44 71 94 94 erytech@newcap.eu |
Attachment
- 220428 ERYTECH_PR_URD_vf
© OMX, source